Patient-reported experience with an immunotherapy telehealth platform.

• DOI: 10.1200/jco.2024.42.16_suppl.1637
• Publication Date: 2024-05-29T17:43:22Z
• Authors: Robert Michael Daly; Erin Mary Bange; Sahil D Doshi; Bob T. Li; Neil J. Shah; David H Aggen; Ritesh R Kotecha; Juliana Eng; Kenneth K. Ng; Fernanda C. G. Po...; Gilad Kuperman; Allison Lipitz-Sn...; Peter D. Stetson; Deb Schrag; Katherine Panageas; Michael J. Morris
• Keywords: Telehealth

1637 Background: The Making Telehealth Delivery of Cancer Care at Home Effective and Safe for Immunotherapy (MATCHES-IO) intervention seeks to improve the efficiency patient experience those treated with single agent pembrolizumab. Because pembrolizumab is administered as an outpatient infusion every 3-weeks, patients require up 18 clinic visits per year receive treatment, which arduous. During COVID-19 pandemic, FDA granted accelerated approval extended interval dosing 6 weeks, but despite this 3-week remains standard (65% prescriptions) clinicians perceive schedule enables them identify manage toxicity early. may be impetus change more convenient 6-week in person schedule, evidence needed. Methods: We conducted a arm pragmatic trial evaluate telehealth immunotherapy platform non-small cell lung, genitourinary, or melanoma cancers receiving MATCHES-IO evaluates whether in-person therapy q6wk (rather than q3wk), interim checks between treatments, efficient enhances relative q3wk visits. components include clinician-patient virtual visits, labs home, biometric devices home vital sign monitoring, electronic patient-reported outcomes monitor common IO-related toxicities. Patient was assessed after each televisit two televisits. measured survey that included net promoter score, how likely are they recommend similar (scale 0-10, higher score desirable). A 9 greater considered excellent. Results: Between July 2023 February 2024, 27 were enrolled, median age 68 (range 45–85), 74% white, 11% black, Asian, 41% female. types thoracic (59% patients), genitourinary (33%), (7%). 19 (70.4%) have completed survey. 2-10). 94% perceived benefit MATCH-IO including saved time (83% respondents), convenience (83%), caregiver/family (44%), money better monitoring cancer treatment (39%). 78% found visit less stressful visit. Conclusions: Patients endorsed enhanced Further follow-up needed confirm these findings determine improved through fewer